Companies › Guangzhou Lupeng Pharmaceutical Company
3 active drug programs in 13 registered trials: 8 Phase 1, 4 Phase 2, 1 Phase 3; Oncology, Neurology, Other, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rocbrutinib (LP-168) BTK inhibitor | BTK | Phase 3 | Mantle Cell Lymphoma; Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL); Relapsing-remitting Multiple Sclerosis (RRMS) … | Mar 2027 |
| Lacutoclax (LP-108) selective BCL-2 inhibitor | BCL2 | Phase 2 | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Acute Myeloid Leukemia | Dec 2027 |
| LP-128 | – | Phase 1 | Chronic Hepatitis b | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05716087 | Rocbrutinib (LP-168) | Phase 2 | Mantle Cell Lymphoma (MCL) | Oncology | Dec 2024 |
| NCT07374224 | Rocbrutinib (LP-168) | Phase 1 | Clinical Pharmacology | Other | Jun 2026 |
| NCT05130567 | LP-128 | Phase 1 | Chronic Hepatitis b | Infectious disease | Dec 2026 |
| NCT04993690 | Rocbrutinib (LP-168) | Phase 1 | B-cell Lymphoma | Oncology | Mar 2027 |
| NCT06251180 | Rocbrutinib (LP-168) | Phase 1 | B-cell Non-Hodgkin Lymphoma | Oncology | Jun 2027 |
| NCT07189065 | Rocbrutinib (LP-168) | Phase 2 | Diffuse Large B-Cell Lymphoma (DLBCL) | Oncology | Dec 2027 |
| NCT07570017 | Rocbrutinib (LP-168) | Phase 1 | DLBCL | Oncology | Dec 2027 |
| NCT05641259 | Lacutoclax (LP-108) | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
| NCT07609823 | Lacutoclax (LP-108) | Phase 2 | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Oncology | Mar 2028 |
| NCT07776743 | Rocbrutinib (LP-168) | Phase 2 | Relapsing-remitting Multiple Sclerosis (RRMS) | Neurology | Jun 2028 |
| NCT07609862 | Rocbrutinib (LP-168) | Phase 1 | Mantle Cell Lymphoma (MCL) | Oncology | Jun 2029 |
| NCT07609862 | Rocbrutinib (LP-168) | Phase 1 | Mantle Cell Lymphoma (MCL) | Oncology | Jun 2029 |
| NCT07377578 | Rocbrutinib (LP-168) | Phase 3 | Mantle Cell Lymphoma | Oncology | May 2031 |
BeOne Medicines Ascentage Pharma Group Sanofi Eli Lilly AbbVie AstraZeneca Zenas BioPharma (USA) Carna Biosciences Merck & Co. (MSD) Acerta Pharma
NOBO Medicine TransThera Sciences (Nanjing) Shanghai Fosun Pharmaceutical Industrial Development Dizal Pharmaceuticals Nurix Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.